This user has not added any information to their profile yet.
Wigilya P. Mikomangwa is a Lecturer in the Department of Clinical Pharmacy and Pharmacology, School of Pharmacy, Muhimbili University of Health and Allied Sciences (MUHAS), Tanzania. He is a registered pharmacist and holds PhD from the Department of Epidemiology and Biostatistics at the School of Public Health, MUHAS.
He completed the NIH-supported HIV Implementation Science (HIS) Training Program fellowship at Harvard T.H. Chan School of Public Health, USA, and the Hard-to-Reach Research Program fellowship at the University of California, San Francisco (UCSF), USA. He was also a Young East African Research Scientist Fellow under the East African Health Research Commission (EAHRC). His doctoral training was supported by the DOCEHTA Programme, a collaborative PhD partnership between Muhimbili University of Health and Allied Sciences (MUHAS), Tanzania, and the University of Oslo, Norway. In addition, he has received competitive research funding and training support through the GSK Africa Open Lab, the Swedish International Development Cooperation Agency (Sida), and the MRC/NIHR Trials Methodology Research Partnership.
His research focuses on HIV/AIDS, tuberculosis, malaria, antimicrobial resistance, implementation science, pharmacoepidemiology and pharmacovigilance, with the aim of generating evidence to inform policy, strengthen health systems, and improve population health outcomes. He has authored and co-authored more than 30 peer-reviewed publications in international journals, contributing to advances in HIV prevention, malaria prevention and treatment, antimicrobial stewardship, clinical pharmacy, and global public health.
Interested in public health, implementation research, pharmacoepidemiology (and pharmacovigilance) with focusing on the following but not limited to:
1. HIV/AIDS prevention and treatment, particularly HIV pre-exposure prophylaxis (PrEP), antiretroviral therapy adherence, retention in HIV care, and implementation of evidence-based HIV interventions among special, vulnerable and key populations.
2. Malaria prevention and control, including intermittent preventive treatment during pregnancy (IPTp), antimalarial drug use, malaria case management, and antimalarial drug resistance.
3. Tuberculosis and other infectious diseases, with an emphasis on improving prevention and treatment strategies.
4. Antimicrobial resistance (AMR) and antimicrobial stewardship, including rational antibiotic use, prescribing practices, dispensing behaviors, and interventions to reduce inappropriate antimicrobial use.
5. Clinical pharmacy and pharmacotherapy, focusing on optimization of medicine use, pharmaceutical care, medication safety, adverse drug reactions, and integration of pharmacists into patient-centered healthcare.
6. Pharmacoepidemiology, pharmacovigilance and implementation science: evaluating the safety, effectiveness, adoption, and scale-up of public health interventions to strengthen health systems.
7. Maternal, child, and public health, including medicine use during pregnancy, pediatric pharmacotherapy, and community-based disease prevention programs.
Current research activities:
1. Designing and conducting clinical, epidemiological, and implementation science studies using quantitative, qualitative, and mixed-methods approaches.
2. Leading and collaborating on multicenter research projects in HIV, malaria, antimicrobial stewardship, and pharmaceutical capacity and systems strengthening.
3. Translating research findings into evidence that supports health policy, clinical guidelines, and healthcare practice.
4. Supervising and mentoring undergraduate and postgraduate students while contributing to teaching in clinical pharmacy and pharmacology.
5. Building research capacity through international collaborations
1. Evaluation of facility-based PrEP program among at-risk women in Tanzania| PREPTA/DOCEHTA| 2022-2026| Principal Investigator
2. Enhancing the Optimization of Empirical Antibiotic Therapy: Development and Implementation of mobile Antibiograms in Tertiary Hospitals in Tanzania| GSK Africa Open Lab| 2025-2027| Co-Principal Investigator
3. Evaluation of policy implementation of Isoniazid Preventive Therapy among Children living with HIV in Rural Tanzania|Sida| 2022-2023| Co-Principal Investigator
4. Prevalence and determinants of adverse drug reactions among HIV positive patients on antiretroviral| Sida | 2022.02-2022.12| Co-Principal Investigator
5. Assessment of the challenges encountered in implementing vaccine clinical trial methodologies in low income countries| MRC/NIHR Trials Methodology| 2020-2021 | Principal Investigator
6.Susceptibility profile of antibiotics reserved (meropenem, cefepime, clindamycin) for use in tertiary hospitals in Tanzania. Sida. 2019-2020
7. Uptake of intermittent preventive treatment in pregnant women with Sulfadoxine-Pyrimethamine and associated maternal and fetal birth outcomes in
a low malaria transmission setting in Tanzania| Sida| 2017-2020 | Principal Investigator
1. Mikomangwa WP, Metta E, Moen K, et al. Longitudinal Patterns of Adherence to Oral HIV Pre-Exposure Prophylaxis Among At-Risk Women in Tanga, Tanzania: A Convergent Analysis of Influencing Factors and Optimization Strategies. AIDS Behav. Published online June 5, 2026. doi:10.1007/s10461-026-05187-2
2. Mikomangwa WP, Moen K, Mmbaga EJ, et al. Early and Long-Term Retention in Facility-Based HIV Pre-Exposure Prophylaxis Service Delivery Model Among Women at High Risk of HIV Acquisition in Tanga, Tanzania. HIV AIDS (Auckl). 2026;18:604257. Published 2026 Jun 15. doi:10.2147/HIV.S604257
3. Mikomangwa WP, Metta E, Moen K, et al. "I Stopped to Prove them Wrong:" Reasons for Discontinuing Daily Oral HIV Pre-exposure Prophylaxis Among Women at High Risk of HIV in Tanzania-A Convergent Mixed Methods Study. AIDS Behav. 2026;30(2):355-367. doi:10.1007/s10461-025-04879-5
4. Mikomangwa WP, Moen K, Mmbaga EJ, et al. HIV pre-exposure prophylaxis use during periods of unprotected sex among female sex workers in Tanga city, Tanzania: a control arm analysis of the pragmatic quasi-experimental trial. Front Public Health. 2024;12:1405765. Published 2024 Jul 16. doi:10.3389/fpubh.2024.1405765
5. Bwire GM, Nyondo GG, Njiro BJ, Aiko BG, Mikomangwa WP et al. Strengthening HIV Programs in Sub-Saharan Africa Through Implementation Research: A Mixed-Methods Systematic Review. AIDS Res Treat. 2026;2026:7185732. Published 2026 Jun 13. doi:10.1155/arat/7185732
6. Mbwambo DP, Mikomangwa WP, Mkugwe RH, et al. Skin-related adverse events and their associated factors among Diabetic patients on insulin therapy. PLoS One. 2026;21(2):e0320556. Published 2026 Feb 2. doi:10.1371/journal.pone.0320556
7. Coelho DRA, Njiro BJ, Yussuf MH, Mikomangwa WP et al. Cognitive behavioral therapy for antiretroviral therapy adherence and treatment outcomes among people living with HIV: a systematic review and meta-analysis. Nat Ment Health. 2025;3(6):735-746. doi:10.1038/s44220-025-00444-0
8. Bwire GM, Ngasala B, Mikomangwa WP, Kilonzi M, Kamuhabwa AAR. Detection of mutations associated with artemisinin resistance at k13-propeller gene and a near complete return of chloroquine susceptible falciparum malaria in Southeast of Tanzania. Sci Rep. 2020;10(1):3500. Published 2020 Feb 26. doi:10.1038/s41598-020-60549-7
9. Mikomangwa WP, Minzi O, Mutagonda R, et al. Effect of sulfadoxine-pyrimethamine doses for prevention of malaria during pregnancy in hypoendemic area in Tanzania. Malar J. 2020;19(1):160. Published 2020 Apr 19. doi:10.1186/s12936-020-03234-4
10. Mikomangwa WP, Oms M, Aklillu E, Kamuhabwa AAR. Adverse birth outcomes among mothers who received intermittent preventive treatment with Sulphadoxine-Pyrimethamine in the low malaria transmission region. BMC Pregnancy Childbirth. 2019;19(1):236. Published 2019 Jul 8. doi:10.1186/s12884-019-2397-1
11. Mikomangwa WP, Bwire GM, Kilonzi M, et al. The Existence of High Bacterial Resistance to Some Reserved Antibiotics in Tertiary Hospitals in Tanzania: A Call to Revisit Their Use. Infect Drug Resist. 2020;13:1831-1838. Published 2020 Jun 17. doi:10.2147/IDR.S250158
12. Bwire GM, Mikomangwa WP, Kilonzi M. Occurrence of septuple and elevated Pfdhfr-Pfdhps quintuple mutations in a general population threatens the use of sulfadoxine-pyrimethamine for malaria prevention during pregnancy in eastern-coast of Tanzania. BMC Infect Dis. 2020;20(1):530. Published 2020 Jul 22. doi:10.1186/s12879-020-05253-7
13. Mwakawanga DL, Mutagonda RF, Mlyuka HJ, Mikomangwa WP et al. Improving the provision of clinical pharmacy services in low- and middle-income countries: a qualitative study in tertiary health facilities in Tanzania. BMJ Public Health. 2025;3(1):e001776. Published 2025 Jan 20. doi:10.1136/bmjph-2024-001776
14. Minzi OM, Kilonzi M, Mikomangwa WP, et al. Update on bacterial and antibiotic susceptibility profiles among patients attending a tertiary referral hospital in Tanzania. J Glob Antimicrob Resist. 2021;25:87-88. doi:10.1016/j.jgar.2021.02.030
15. Mikomangwa WP, Kaaya C, Kilonzi M, Mlyuka H, Marealle AI, Mutagonda R. Level of knowledge among health care providers on preparation of injectable artesunate for treatment of severe malaria in public health facilities in Tanzania. BMC Res Notes. 2019;12(1):224. Published 2019 Apr 11. doi:10.1186/s13104-019-4257-5
